Literature DB >> 1975829

Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response.

N G Chakraborty1, D R Twardzik, M Sivanandham, M T Ergin, K E Hellstrom, B Mukherji.   

Abstract

The host immune response toward autologous human cancer is subject to regulation by the immunoregulatory network. We show that certain CD4+ T cell clones, derived from melanoma involved lymph node lymphocytes and from PBL stimulated by autologous melanoma cells, selectively down-regulated the induction of cytotoxic immune response of PBL against the respective autologous melanoma cells in two autologous systems. In both systems, only the generation of cytotoxic response against the autologous melanoma cells were suppressed. Cytotoxic response against EBV-infected autologous lymphoblastoid cell line in one case and cytotoxic responses against allogeneic targets in the other were not affected. In addition to suppressor activity selectively expressed against the autologous melanoma cells, the T cell clones up-regulated their Tac receptors when cocultured with the autologous melanoma cells and APC. These results support the existence of a putative tumor Ag-driven activation of regulatory T cells that affect cytotoxic immune response, in vitro, against autologous human melanoma.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1975829

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination.

Authors:  Matteo Vergati; Vittore Cereda; Ravi A Madan; James L Gulley; Ngar-Yee Huen; Connie J Rogers; Kenneth W Hance; Philip M Arlen; Jeffrey Schlom; Kwong Y Tsang
Journal:  Cancer Immunol Immunother       Date:  2010-10-26       Impact factor: 6.968

2.  Tumor-derived cytokines induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor beta.

Authors:  M R Young; M A Wright; M Coogan; M E Young; J Bagash
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Analysis of circulating regulatory T cells (CD4+CD25+CD127-) after cryosurgery in prostate cancer.

Authors:  Tong-Guo Si; Jun-Ping Wang; Zhi Guo
Journal:  Asian J Androl       Date:  2013-06-03       Impact factor: 3.285

Review 4.  Regulatory T cells and innate immune regulation in tumor immunity.

Authors:  Rong-Fu Wang
Journal:  Springer Semin Immunopathol       Date:  2006-07-13

5.  Increasing infiltration and activation of CD8+ tumor-infiltrating lymphocytes after eliminating immune suppressive granulocyte/macrophage progenitor cells with low doses of interferon gamma plus tumor necrosis factor alpha.

Authors:  M R Young; G McCloskey; M A Wright; A S Pak
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

6.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.

Authors:  L Ferradini; A Mackensen; C Genevée; J Bosq; P Duvillard; M F Avril; T Hercend
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 7.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 8.  Immunoregulatory T cells: role and potential as a target in malignancy.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

Review 9.  Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.

Authors:  Shirin Karimi; Subhasis Chattopadhyay; Nitya G Chakraborty
Journal:  Immunology       Date:  2015-02       Impact factor: 7.397

10.  Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells.

Authors:  R S Selvan; T N Pappas; F E Ward
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.